Skip to main content
Clinical Trials/NCT06734286
NCT06734286
Recruiting
Not Applicable

CogMed Intervention Targeting Working Memory in Patients with Mild Cognitive Impairment

St. Joseph's Hospital and Medical Center, Phoenix1 site in 1 country10 target enrollmentSeptember 16, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mild Cognitive Impairment (MCI)
Sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Enrollment
10
Locations
1
Primary Endpoint
Working Memory as measured by the WAIS-IV Digit Span Forward/Backward
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The purpose of this study is to test whether a special memory training program, called CogMed, can help people with early memory problems. The Investigators want to see if this training improves memory and also helps reduce stress.

The Investigators also want to see if CogMed results in changes to a blood biomarker called p-Tau 217, which possibly indicate Alzheimer's disease (AD).

Detailed Description

The goal of this study is to conduct a pilot clinical trial aimed at comparing the effects of CogMed intervention plus Treatment As Usual (TAU) versus TAU alone in patients with Mild Cognitive Impairment (MCI). Based on our preliminary data from brain health program, the primary hypothesis is that the CogMed intervention may improve the CogMed measures and possibly working memory. This may improve sense of self-efficacy and lead to a decrease in perceived stress, thereby demonstrating possible transfer of cognitive benefits to biobehavioral construct of perceived stress. Additionally, the study aims to demonstrate the feasibility of collecting p-Tau 217, a blood based Alzheimer's Disease biomarker, from MCI patients. Though no significant changes in pTau 217 are expected due to the short duration of the study, the goal is to successfully recruit 10 MCI patients (5 in the intervention group and 5 in the control group) who are willing to undergo blood draws for p-Tau 217 level determination.

Registry
clinicaltrials.gov
Start Date
September 16, 2024
End Date
September 30, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Responsible Party
Principal Investigator
Principal Investigator

Yonas Geda

Principal Investigator, M.D.

St. Joseph's Hospital and Medical Center, Phoenix

Eligibility Criteria

Inclusion Criteria

  • Male or female outpatients ages ≥ 50 years;
  • Meet Mayo Clinic Criteria for MCI. (Patients with mild cognitive impairment)
  • Access to the internet through computer
  • A proficiency in speaking and reading English or having a family member who is proficient in reading and speaking English and is willing to serve as a translator.
  • Vision and hearing must be sufficient to comply with study procedures.

Exclusion Criteria

  • Mini Mental State Exam (MMSE) score less than 19 or patients diagnosed with moderate or severe dementia by a clinician.
  • In the opinion of the investigator, participation would not be in the best interest of the subject.

Outcomes

Primary Outcomes

Working Memory as measured by the WAIS-IV Digit Span Forward/Backward

Time Frame: Will be assessed at baseline and again at a 3-month follow-up following the intervention period.

The Digit Span Forward/Backward is a subset of the Wechsler Adult Intelligence Scale (WAIS) that captures attention efficiency and working memory.

Working Memory as measured by the TMT-B

Time Frame: Will be assessed at baseline and again at a 3-month follow-up following the intervention period.

The Trail Making Test (TMT) is a well-established test sensitive to impairment in multiple cognitive domains.

Working Memory as measured by Category Fluency Test

Time Frame: Will be assessed at baseline and again at a 3-month follow-up following the intervention period.

The Category Fluency Test (CFT) was created to assess semantic fluency. It consists of asking the individual to name as many animals as possible in 60 s. Performance on CFT can be evaluated through several components, such as the number of correct words, clusters, switching, related words, and intrusion and perseveration errors.

Secondary Outcomes

  • Change in Blood biomarker(Will be assessed at baseline and again at a 3-month follow-up following the intervention period.)
  • Perceived Stress Scale (PSS) Score(Will be assessed at baseline and again at a 3-month follow-up following the intervention period.)
  • Brief Resilience Scale (BRS) Score(Will be assessed at baseline and again at a 3-month follow-up following the intervention period.)
  • Pittsburgh Sleep Quality Index (PSQI) Score(Will be assessed at baseline and again at a 3-month follow-up following the intervention period.)
  • Physical Activity and Sedentary Behavior Questionnaire Score(Will be assessed at baseline and again at a 3-month follow-up following the intervention period.)
  • WHO Quality of Life Questionnaire(Will be assessed at baseline and again at a 3-month follow-up following the intervention period.)
  • Memory as measured by the Comprehensive Trail Making Test (CTMT)(Will be assessed at baseline and again at a 3-month follow-up following the intervention period.)
  • Cognitive Impairment as measured by the Mini Mental State Examination (MMSE)(Will be assessed at baseline and again at a 3-month follow-up following the intervention period.)
  • Verbal Memory as Measured by the Auditory Verbal Learning Test (AVLT)(Will be assessed at baseline and again at a 3-month follow-up following the intervention period.)
  • Mediterranean Diet Scale(MedDiet)(Will be assessed at baseline and again at a 3-month follow-up following the intervention period.)
  • Comprehensive Assessment of Acceptance and Commitment Therapy Process (CompACT)(Will be assessed at baseline and again at a 3-month follow-up following the intervention period.)

Study Sites (1)

Loading locations...

Similar Trials